Expression of inflammatory and structural matrix genes in synovial fluid following intra-articular administration of isoflupredone acetate to exercised horses.

This study evaluates the effects of a corticosteroid, isoflupredone acetate (IPA), on the expression of certain inflammatory and structural genes in horses that have been exercised, seeking to understand its role in suppressing inflammation and promoting healing in treated joints.

Study Objective, Design, and Methodology

• The study aimed to assess the effects of IPA on the expression of chosen anti- and pro-inflammatory and structural matrix genes in Thoroughbred horses that underwent exercise. It also attempted to link these effects with the concentration levels of IPA.
• The experiment involved a block design model conducted on twelve horses. These horses were subjected to a single intra-articular (within the joint) administration of 8mg of IPA or a 0.9% saline solution.
• Synovial fluid samples, which lubricates the joints, were collected before and up to 42 days after IPA administration in the treated joints. Microarray analysis and quantitative reverse transcription PCR (qRT-PCR), which are methods used for DNA sequencing and gene expression study, were performed on these samples.

Results and Findings

• The microarray analysis indicated that hundreds to thousands of genes exhibited a measurable change in expression levels when comparing the baseline (pre-administration) samples to samples taken at 24 hours and 7 days post-administration.
• More specific qRT-PCR analysis showed that the expression of ANXA-1, an anti-inflammatory gene, significantly increased, while the expression of pro-inflammatory and matrix modifying genes IL23A and MMP1 and MMP9 significantly decreased after the administration of IPA. There were no significant differences observed in the expression levels of genes responsible for collagen production from the baseline.
• The changes in gene expression suggested that IPA likely had a prolonged therapeutic effect lasting beyond the detection time in both blood plasma and synovial fluid, making it a potentially effective treatment for joint inflammation and damage in horses.

Limitations and Conclusion

• The study’s limitations include the use of a noninflammatory model, implying that the results could vary in the presence of an acute inflammatory condition. Furthermore, the inability to measure the protein concentrations of inflammatory mediators due to limited synovial fluid sample volume was a constraint.
• The overall conclusion is that the expression relative to baseline, for both inflammatory and matrix genes for up to 42 days post IPA administration, suggests a prolonged effect relative to detection time in both plasma and synovial fluid. This indicates the potential of IPA, a FDA-approved corticosteroid, in the treatment of joint inflammation and damage in horses.